Table: cancer immunotherapy
[['antibody', 'brand name', 'approval date', 'type', 'target'], ['alemtuzumab', 'campath', '2001', 'humanized', 'cd52'], ['bevacizumab', 'avastin', '2004', 'humanized', 'vascular endothelial growth factor'], ['brentuximab vedotin', 'adcetris', '2011', 'chimeric', 'cd30'], ['cetuximab', 'erbitux', '2004', 'chimeric', 'epidermal growth factor receptor'], ['gemtuzumab ozogamicin', 'mylotarg', '2000', 'humanized', 'cd33'], ['ibritumomab tiuxetan', 'zevalin', '2002', 'murine', 'cd20'], ['panitumumab', 'vectibix', '2006', 'human', 'epidermal growth factor receptor'], ['rituximab', 'rituxan , mabthera', '1997', 'chimeric', 'cd20'], ['trastuzumab', 'herceptin', '1998', 'humanized', 'erbb2']]
Statement: 2 Antibody were approved for Cancer Immunotherapy in 2004
Statement: Zevalin and Rituxan has the same Target , just as Erbitux and Vectibix have the same Target
Statement: most of the Antibody that were approved were Humanized
Statement: the most recent Brand to get approved was adcertris
Statement: Zevalin is the only Brand that was Type Murine